AURA
Aura Biosciences, Inc. (AURA) Economic Moat Analysis (2026)
Overall Score
Profitability Returns
TTM margins are effectively zero, with gross/EBIT/EBITDA/operating/net profit margins all at 0.0, indicating no current operating profitability.
Returns remain deeply negative, including ROA of -37.6%, ROE of -73.2%, and ROIC of -41.6%, which argues against any durable moat today.
Balance Sheet Liquidity
Liquidity is very strong with a current ratio of 16.8x and cash ratio of 3.47x, giving the company substantial near-term flexibility.
Leverage is low, with debt-to-equity at 0.05x and debt-to-assets at 0.05x, though the solvency ratio is negative and reflects weak earnings power.
Cash Generation
Cash generation is negative, with operating cash flow of -$102.7M and free cash flow of -$102.7M TTM.
Cash flow yields are also negative, including FCF yield of -12.7% and operating cash flow yield of -7.4%, showing no evidence of moat-supported cash conversion.
Valuation Support
The stock screens optically cheap on asset-based measures, with price-to-book at 2.34x and net current asset value of $296.2M.
However, earnings and cash flow multiples are not meaningful in a positive sense because TTM earnings and cash flow are negative, limiting valuation support from fundamentals.
Moat Evidence
There is no visible evidence of pricing power or scale advantage in the current TTM data, as margins are zero and returns on capital are deeply negative.
The balance sheet is liquid, but the absence of profitability and positive cash generation suggests no durable economic moat is currently demonstrated.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Aura Biosciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

